珠海市妇幼保健院重型β-地中海贫血患儿的治疗现状及不规范治疗原因

摘要
图/表
参考文献(16)
相关文章 (15)

全文: PDF (0 KB) HTML (34 KB)
输出: BibTeX | EndNote (RIS)

摘要目的调查重型β-地中海贫血（β-TM）患儿不规范治疗情况及原因，以减少不规范治疗比例，提高患儿的生存状态。方法选取2018年1～12月珠海市妇幼保健院收治的57例β-TM患儿作为研究对象，调查其输血、祛铁、铁过载情况、不规范治疗的原因。结果 57例β-TM患儿中，不规范输血患儿13例（22.8%），不规范祛铁患儿17例（34.0%）。57例β-TM患儿中，不规范输血原因分别为家庭经济困难10例（17.5%），家长不重视3例（5.3%）；50例需使用祛铁药物的患儿中，不规范祛铁原因分别为家庭经济困难11例（22.0%），药物副作用3例（6.0%），家长不重视3例（6.0%）。规范输血患儿与不规范输血患儿的血清铁蛋白（SF）水平比较，差异无统计学意义（P＞0.05）；不规范祛铁患儿的SF水平高于规范祛铁患儿，差异有统计学意义（P＜0.05）。结论 β-TM患儿的不规范治疗比例偏高，大部分与经济困难有关，增加未成年人医疗保险受益人群有助于降低不规范治疗比例，改善患儿预后。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	段丽
	黎瞳
	王峰

关键词 ：重型&beta, -地中海贫血, 儿童, 治疗, 铁过载

Abstract：Objective To investigate the non-standard treatments of children with β-thalasemiamajor(β-TM)and its causes,so as to reduce the proportion of non-standard treatments and improve the survival status of children.Methods A total of 57 cases of β-TM children treated in Zhuhai Municipal Maternity and Child Healthcare Hospital from January to December in 2018 were selected as the subjects,and the blood transfusion,iron removal,iron overload and the causes of non-standard treatment were investigated.Results Among the 57 children with β-TM,there were 13 children(22.8%)with irregular blood transfusion and 17 children(34.0%)with non-normative iron removal.Among the 57 children with β-TM,the reasons for irregular blood transfusion were 10 cases(17.5%)of family financial difficulties,and 3 cases(5.3%)of parents′neglect.Among the 50 children who needed to use iron removing drugs,the causes of nonnormative iron removal were 11 cases(22.0%)of family financial difficulties,3 cases(6.0%)of side effects of drugs,and 3 cases(6.0%)of parents′neglect.There was no significant difference in serum ferritin(SF)between regular and irregular blood transfusion groups(P＞0.05).The SF level in non-normative iron-removing group was higher than that in normative iron-removing group,and the difference was statistically significant(P＜0.05).Conclusion The proportion of non-standard treatments of children withβ-TM is high,most of which are related to economic difficulties.Increasing the income of medical insurance forminors will help to reduce the proportion of non-standard treatments and improve the prognosis of children with β-TM.

Key words： &beta -thalasemiamajor Children Treatment Iron overload

引用本文:

段丽；黎瞳；王峰. 珠海市妇幼保健院重型β-地中海贫血患儿的治疗现状及不规范治疗原因[J]. 中国当代医药, 2020, 27(9): 159-162.
DUAN Li； LI Tong； WANG Feng. Current status of treatment for children with β-thalassem ia major in Zhuhai Municipal Maternity and Child Healthcare Hospital and reasons for non-standard treatment. 中国当代医药, 2020, 27(9): 159-162.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2020/V27/I9/159

[1]	Orkin SH.Recentadvances in globin research using genomewide association studies and gene editing[J].Ann N Y Acad Sci，2016，1368（1）：5-10.
[2]	Sankaran VG，Xu J，Orkin SH.Advances in the understanding of haemoglobin switching[J].Br JHaematol，2010，49（2）：181-194.
[3]	中华医学会儿科学分会血液学组.重型β地中海贫血的诊断和治疗指南[J].中华儿科杂志，2018，56（10）：724-729.
[4]	中华医学会血液学分会/中国医师协会血液科医师分会.铁过载诊断与治疗的中国专家共识[J].中华血液学杂志，2011，32（8）：572-574.
[5]	Cappellini MD，Cohen A，Poter J，et al.Guidelines for the management of transfusion-dependent thalassaemia[Z].2014：2897.
[6]	Angelucci E，Barosi G，Camaschella C，et al.Italian society of hematology practice guidelines for the management of iron overload in thalassemiamajor and related disorders[J].Haematologica，2008，93（5）：741-752.
[7]	Cappellini MD，Cohen A，Eleftheriou A，et al.Guidelines forthe clinical management of thalassaemia[M].2nd revised edition.Nicosia （CY）：Thalassaemia International Federation，2008.
[8]	王燕燕，李晓辉，徐西华.地中海贫血诊治进展与我国现状[J].中国实用儿科杂志，2013，28（6）：473-476.
[9]	方建培，许吕宏.规范儿童重型β地中海贫血的诊治[J].中华儿科杂志，2010，48（3）：166-169.
[10]	周楠，金姣，黄璟，等.地中海贫血患儿家庭负担状况及其影响因素分析[J].中国实用儿科杂志，2018，33（12）：1004-1008.
[11]	赵雪丽.桂西地区重型β地中海贫血儿童生长发育及铁过载状况的调查研究[D].南宁：广西医科大学，2015.
[12]	刘兴玲，吴月勤，李惠森，等.126例重型β地中海贫血患儿输血治疗状况的调查[J].护理学报，2013，21（23）：19-22.
[13]	Filosa A，Vitrano A，Rigano P，et al.Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemiamajor[J].Blood cells Mol Dis，2013，51（2）：85-88.
[14]	Haghpanah S，Zarei T，Zahedi Z，et al.Compliance and satisfaction with defer-asirox（ExjadeR）compared with deferoxamine in patients with transfusion-dependentbeta thalassemia[J].Hematology，2014，19（4）：187-191.
[15]	Pepe A，Meloni A，Rossi G，et al.Cardiac and hepatic iron and ejection fraction in thalassemia major：multicentre prospective comparison of combined deferiprone and defer oxamine therapy against deferiprone or deferoxamine monotherapy[J].JCardiovasc Magn Reson，2013，88（8）：652-656.
[16]	Kwiatkowski JL.Current recommendations for chelation for transfusion-dependent thalassemia[J].Ann N Y Acad Sci，2016，1368（1）：107-114.